Navigation Links
HUYA Bioscience International Announces Partnership with Changzhou Center for Biotech Development
Date:8/18/2014

SAN DIEGO, Aug. 18, 2014 /PRNewswire/ -- HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today  announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD). This partnership will focus on advancing the worldwide potential of innovations from bio-pharmaceutical companies located in Changzhou that could meet critical global pharmaceutical pipeline needs.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is focused on speeding the development and value creation for China sourced novel biopharmaceutical compounds in world-wide markets. HUYA has established a series of collaborations with leading universities and research institutes throughout China and has pioneered in-licensing of both preclinical and clinical stage compounds from the country.

The CZCBD, an institutional unit fully funded and supervised by the Changzhou Science & Technology Bureau, is the first biotechnology development center to operate under local government supervision. It is dedicated to establishing a comprehensive bio-pharmaceutical innovation system and to transforming the output of the more than 800 biotechnology and pharmaceutical companies based within Changzhou. These companies and enterprises represent fields including biopharmaceuticals, chemical drugs, medical devices, equipment and consumables, traditional Chinese medicine, industrial biology, bioagriculture, bioenvironmental protection and bioenergy.

This partnership enables HUYA and CZCBD to collaborate on promoting new drug development in China and worldwide. Local biopharmaceutical companies serviced by CZCBD will be able to leverage HUYA's global biopharmaceutical knowledge and network, and consult with HUYA's team of experts in drug development and commercialization. In turn, HUYA will have the right of priority review to evaluate certain research and development projects of local companies supported by CZCBD, providing advice and consultation as needed.

"HUYA is delighted to work with the prestigious Changzhou Center for Biotech Development in a partnership that aims to advance the development and commercialization of innovative pharmaceutical compounds and biomarkers," said Clement Gingras, HUYA's Chief Technology Officer and Chief Operating Officer Asia. "We are very excited about this partnership and look forward to fruitful collaborations in the years to come."

Xin Zhou, Director of the Changzhou Center for Biotech Development, also expressed optimism about this collaboration. "This partnership connects Changzhou's resources in biomedical science and technology with HUYA's experience and resources in international new drug development, broadens access to worldwide markets for Changzhou's biomedical companies, and accelerates the global reach of innovative pharmaceutical technologies and products from Changzhou."

About HUYA Bioscience International
HUYA Bioscience International is a leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value for biopharmaceutical innovation in China. HUYA has offices in the US, the UK, Japan and in eight strategic locations across China, with joint headquarters in San Diego and Shanghai. HUYA's team is practiced in leading pharmaceuticals and medical devices through FDA and PMDA submission and approval all the way to commercialization. www.huyabio.com

About Changzhou Center for Biotech Development
Changzhou Center for Biotechnology Development (CZCBD) is an institutional unit fully funded and supervised by the Changzhou Science & Technology Bureau.  The center was renamed from the Changzhou Institute of Ecological Technology Application and approved by Changzhou City on January 11, 2013.  The main responsibilities of CZCBD are participating in the formulation of policy plans for S&T projects, integrating resources of biotech and related industries, facilitating biotech innovation and development, and providing services for agricultural biotech innovation and agricultural modernization.  The center's goal is to become the city's management and coordination center for biotech industry, policy research center, S&T project management center, industry consulting service center, coordinating center for international cooperation, talents development center, and center for international exchange of biotechnologies and industry information.
www.czcbd.org.cn/sw/

Contact
Clement Gingras
CTO and COO Asia
HUYA Bioscience International
+1.858.798.8800
cgingras@huyabio.com

Lara Cresswell
VP, Public Relations
HUYA Bioscience International
+447939228491
lcresswell@huyabio.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):